Geron Corporation (NASDAQ:GERN) is one of the most promising penny stocks under $5 to buy. On February 25, Geron Corporation reported earnings results for Q4 and the full year of 2025, fueled by the commercial success of its first-in-class telomerase inhibitor, RYTELO. The company achieved $48 million in net product revenue for Q4 and $183.6 million for the full year. This growth was supported by a 9% increase in demand and the expansion of its ordering accounts to ~1,300.
Strategically, Geron underwent a significant transition in late 2025 to optimize its path toward sustainability. The company implemented a workforce reduction of ~one-third to lower future operating expenses while maintaining its commercial focus. R&D expenses decreased as costs for RYTELO shifted from clinical development to capitalized commercial manufacturing. Meanwhile, the company continues to build a robust body of scientific evidence, with 10+ investigator-sponsored trials underway and new data expected in H2 2026 regarding RYTELO’s use in real-world settings and earlier lines of treatment.
egyjanek/Shutterstock.com
For 2026, Geron Corporation reiterated its financial guidance, projecting RYTELO net product revenue between $220 and $240 million. Beyond US commercial growth, the company is focused on the IMpactMF interim analysis in relapsed/refractory myelofibrosis and exploring pathways to bring RYTELO to international markets.
Geron Corporation is a commercial-stage biopharmaceutical company that develops therapeutic products for oncology. It offers RYTELO, which is a telomerase inhibitor for low to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
